This video examines how a specific combination of KIR/KIR-ligand genotypes in high-risk neuroblastoma patients may be predictive of outcomes when adding dinutuximab to isotretinoin.
Amy K. Erbe, PhD
Advertisement
Articles by Amy K. Erbe, PhD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Approves Relacorilant Combo in Platinum-Resistant Ovarian Cancers
2
Navigating New Horizons in Neuroendocrine Prostate Cancer
3
FDA Clears Investigator-Initiated IND for SRN-101 in Recurrent High-Grade Glioma
4
The Intersection of Technology and Psycho-Oncology Care
5